Special Drug Use-Results Survey of OPDIVO (RCC)

Not Applicable

Completed

• Conditions: Renal Cell Cancer

• Registration Number: JPRN-jRCT1080224010
• Lead Sponsor: ONO PHARMACEUTICAL CO.,LTD.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-07-26
• Study Completion: 2021-02-12
• Results First Posted: 2022-04-20
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: completed
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

All patients with unresectable or metastatic renal cell cancer to whom OPDIVO was administered

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
safety<br>Safety items : Occurrence status of adverse events (including adverse drug reactions)

Secondary Outcome Measures

Name	Time	Method
efficacy<br>Efficacy items : Comprehensive improvement (the best antitumor efficacy by 6 and 12 months after the initiation of OPDIVO or by the end or discontinuation of the treatment)